Roche said on it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and last phase of testing on humans.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem’s t:slim X2 insulin pump. The deal settles all pending and ...

Roche Diagnostics will invest $550 million in its Indianapolis base to construct a new manufacturing facility for glucose monitoring devices, which will add several hundred jobs and further ...

Roche's costs of manufacturing the drug are not significant, with a year of treatment requiring less than 2 grams of risdiplam, which can probably be manufactured by Roche at less than $50,000 ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning the President Trump administration for an exemption. Roche is trying ...

Roche’s share price has fallen by about 18% over the past month, with most of the drop coming after the U.S. tariff announcement on April 2. President Trump says tariffs on pharmaceuticals are ...

Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, making the pharmaceutical giant the latest company to unveil a capital ...

This investment plan is expected to create over 12,000 new jobs, with a thousand at Roche and the remaining 11,000 to serve as support for the new facilities, in addition to 6,500 construction jobs.

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is considering tariffs on drugmakers.

Trontinemab 3.6 mg/kg reduced amyloid below 24 centiloids in 81% of participants after 28 weeks, with mild ARIA-E cases in <5% of patients. Roche's Elecsys pTau181 plasma test showed potential to ...

In April 2024, David Roche’s life nearly ended—but his comeback was just beginning. After a near-fatal bike crash in April 2024, ultrarunner David Roche decided to go all in chasing big goals.

Roche has agreed to pay Zealand $1.65 billion cash upfront—of which $1.4 billion will be due when the deal closes, and the remaining $250 million to be due over the first two anniversaries of ...